MedWatch

Analysts flock to raise Novo Nordisk share price target following upgrade

Equity analysts are very positive when it comes to the Novo Nordisk stock, especially after the pharmaceutical firm upgraded its guidance in connection with its Q1 report on Friday.

Photo: Novo Nordisk / PR

Friday morning last week, Novo Nordisk caught the stock market by surprise when the company released its first quarterly report for 2022 half a week before it was scheduled to be published.

In connection with the report, Novo Nordisk upgraded its guidance for the full-year. Novo is now counting on reaching sales growth of 10–14 percent, up from earlier 6–10 percent, and operating growth of 9–13 percent, versus the former estimate of 4–8 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs